EMA approves TOBI Podhaler (tobramycin inhalation powder) for cystic fibrosis lung infections caused by Pseudomonas aeruginosa; marketed in the EU since July 2011.
Approval Background and Regulatory History
On September 23, 2010, the European Medicines Agency (EMA) issued a positive opinion, and on July 20, 2011, granted full marketing authorization for TOBI Podhaler (tobramycin 28mg inhalation powder capsules, EMA product number EMEA/H/C/002155) for the treatment of chronic pulmonary infections with Pseudomonas aeruginosa in patients with cystic fibrosis (CF). It was designated as an orphan drug in March 2003, and upon approval, it received a 10-year market exclusivity in the EU. The initial marketing authorization holder (MAH) was Novartis Europharm Ltd. In September 2018, Mylan acquired the entire TOBI portfolio for USD 463 million. Following the launch of Viatris (VTRS) in 2020, the MAH was transferred.
Clinical Evidence and Efficacy Data
The EMA approval was primarily based on two clinical trials. In Study 1 (102 pediatric and adolescent patients, ages 6-21), the TOBI Podhaler group showed a 13.2% improvement in forced expiratory volume in one second (FEV₁) after 24 weeks (3 cycles), while the placebo group showed a 0.6% decrease, demonstrating a significant difference in lung function. Study 2 (primarily adult patients, 553) confirmed non-inferiority compared to the existing standard treatment, TOBI (tobramycin nebulizer solution). TOBI Podhaler is an aminoglycoside antibiotic that inhibits protein synthesis in the cell wall of Pseudomonas aeruginosa. The dosage regimen involves administering 4 capsules twice daily (every 12 hours) for 28 days, followed by a 28-day off-treatment period, repeated in cycles.
Competitive Landscape and Market Position
The direct competitors of TOBI Podhaler are Cayston (aztreonam lysine for inhalation) from Gilead Sciences (GILD) and inhaled colistin formulations. The key differentiating factor of TOBI Podhaler is the convenience of the dry powder inhaler (DPI) formulation, which eliminates the need for a nebulizer, reduces the administration time to approximately 6 minutes, and eliminates the need for refrigeration. The global inhaled antibiotics market is estimated at approximately USD 1.2 to 1.5 billion in 2022-2024, with the treatment of P. aeruginosa, a major pathogen in CF patients, being a key segment.
Paradigm Shift in CF Treatment and Structural Challenges
Vertex Pharmaceuticals' (VRTX) Trikafta (elexacaftor/tezacaftor/ivacaftor), approved by the FDA in 2019, rapidly expanded and fundamentally improved lung function in CF patients with the F508del mutation (approximately 90% of all patients), thereby reducing the incidence of Pseudomonas aeruginosa infections. This has created structural pressure on inhaled antibiotics such as TOBI Podhaler, as the influx of new patients has decreased. In contrast to Vertex's CF portfolio sales of approximately USD 9.5 billion in 2023, the inhaled antibiotics market has stagnated.
Changes in Orphan Drug Status and Current Situation
The EU orphan drug exclusivity period of 12 years expired, and it was voluntarily withdrawn in July 2023, which means the entry barrier for generics has disappeared. Regulatory monitoring is ongoing with EPAR revision 25 (last updated May 11, 2026). Viatris operates a portfolio of both branded and generic drugs, so the impact of generic competition on the profitability of branded TOBI Podhaler remains a medium-term challenge.
Mylan's acquisition of the TOBI portfolio from Novartis for USD 463 million in September 2018 reflects the high valuation of the CF inhaled antibiotics market by institutional investors at the time. However, since 2019, Vertex (VRTX)'s Trikafta has shifted the standard of care for CF treatment to CFTR modulators, structurally weakening the long-term growth base of inhaled antibiotics, including TOBI Podhaler. With the expiration of EU orphan drug exclusivity in July 2023, the entry of generics is expected to intensify, which could put pressure on the margins of Viatris (VTRS), the current MAH. In the market competition with Cayston (Gilead, GILD), new research in the field of CF infection treatment is increasingly focused on demonstrating the synergistic effects with CFTR modulators. Investors in the CF field should consider the differentiation strategy of inhaled antibiotic pipelines targeting the approximately 10% of CF patients who do not respond to CFTR modulators as a key evaluation criterion.
Source: EMA (ema)
https://www.ema.europa.eu/en/medicines/human/EPAR/tobi-podhaler